A modeling study projected that HPV vaccination programs for adults aged 27 to 45 years could benefit subgroups at higher risk for HPV, but overall, the approach is more costly and less effective than ...
According to DelveInsight’s analysis, the human papillomavirus market is anticipated to increase during the forecast period (2024–2034), owing to the launch of emerging therapies and healthcare ...
This interesting study presents valuable information on how human cytomegalovirus (HCMV) infection disrupts the activity of the TEAD1 transcription factor, leading to widespread chromatin alterations.
Results that may be inaccessible to you are currently showing.